We have good news in regards to Bristol-Myers Squibb and the head quarters of Mead Johnson in Evansville. Bristol-Myers Squibb plans to keep a majority ownership of Mead Johnson into the foreseeable future, the drug company announced today.

Bristol-Myers said it plans to file a registration statement by the end of the year to sell from 10 percent to 20 percent of its Mead Johnson subsidiary to the public through a stock offering. Speaking during a conference call today, Bristol-Myers executives said the sale would allow Mead Johnson to grow and still give Bristol a steady source of cash.

This is good news for Evansville as there will be not work interruption or job loss. To read the full article, go to http://www.courierpress.com/news/2008/apr/24/25web-MeadJohnson/.